Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.
Authors:
- P J GoodwinPGP J Goodwin
- R FeldRFR Feld
- W K EvansWEW K Evans
- J PaterJPJ Pater
- 1 October 1988
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 6 (10) , 1537-1547
Abstract
An economic evaluation of a randomized trial of cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and vincristine alone or alternating with etoposide (VP-16) and cisplatin in extensive small-cell lung cancer (SCLC) was undertaken. A survival benefit of 1.6 months in favor of alternating chemotherapy was associated with an additional cost of $450 (1984 Canadian dollars) per patient. This translated to a cost of $3,370 per year of life gained. Sensitivity analyses demonstrated that the cost-effectiveness (CEA) of alternating chemotherapy was greatest when treatment was given on an outpatient basis. The results of the evaluation were sensitive to hospitalization rates, but even the most unfavorable analyses revealed the CEA of alternating chemotherapy to be comparable to that of treatments of common nonmalignant diseases. It is concluded that the CEA of alternating chemotherapy for SCLC was favorable when compared with accepted treatments for nonmalignant diseases. The survival benefit seen with alternating chemotherapy was felt to be clinically significant and alternating chemotherapy is recommended as routine therapy for extensive SCLC.Keywords
This publication has 6 references indexed in Scilit:
- Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung CancerAnnals of Internal Medicine, 1987
- A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1985
- Mitomycin C Reused: An in Vitro Cost-Effectiveness StudyJournal of Urology, 1984
- Nonmedical costs to patients and their families associated with outpatient chemotherapyCancer, 1984
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982
- Counting the costs of cancer therapyEuropean Journal of Cancer and Clinical Oncology, 1982